Could a shorter treatment be just as good for AML in the elderly?

NCT ID NCT07407660

Not yet recruiting Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a shorter course of the drug venetoclax (combined with azacitidine) works as well as the standard longer course for older or frail patients with acute myeloid leukemia (AML). The researchers will check bone marrow on day 14 to decide if the drug can be stopped early. The trial plans to enroll 250 participants and compare how many achieve remission within two cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax and azacitidine
What this could lead to: If successful, this could lead to a shorter, less toxic treatment option for elderly or frail patients with acute myeloid leukemia, potentially reducing side effects while maintaining effectiveness.
What could go wrong: This is a phase 3 trial, but it has not yet started recruiting. The shortened course may not be as effective as the standard regimen, and there is a risk of disease progression or relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.